Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 1 / 2 Trials for Aldesleukin (DB00041)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01823198Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesTreatment